Tech Center 1600 • Art Units: 1632
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17286334 | METHOD FOR ACTIVATION/PROLIFERATION OF T CELLS | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17794166 | TRANSPOSON SYSTEMS FOR GENOME EDITING | Non-Final OA | The Regents of the University of California |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | Non-Final OA | Novartis AG |
| 17692778 | ACOUSTIC REMOTE CONTROL OF MICROBIAL IMMUNOTHERAPY | Non-Final OA | California Institute of Technology |
| 18000414 | LARGE-SCALE PRODUCTION OF EXOSOMES FROM PRIMED MESENCHYMAL STROMAL CELLS FOR CLINICAL USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17755881 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17920599 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEROF | Final Rejection | The Regents of the University of Michigan |
| 17429452 | GENETICALLY MODIFIED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING | Non-Final OA | Regents of the University of Minnesota |
| 17603329 | CRISPR/CAS-BASED GENOME EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION | Non-Final OA | Duke University |
| 17054791 | RAAV VECTORS ENCODING OF LYSOSOMAL BETA-GALACTOSIDASE (GLB1) AND CATHEPSIN A | Non-Final OA | University of Massachusetts |
| 17293355 | METHOD FOR PRODUCING BRAIN ORGANOIDS | Non-Final OA | KEIO UNIVERSITY |
| 17985765 | MUTATION-INDEPENDENT GENE KNOCK-IN THERAPY TARGETING 5' UTR | Non-Final OA | City University of Hong Kong |
| 18658989 | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | Non-Final OA | Figene, LLC |
| 17631478 | DIMETHYLMONOTHIOARSINIC ACID-INDUCED MALIGNANTLY TRANSFORMED CELL LINE OF HUMAN KERATINOCYTES AND USE THEREOF | Non-Final OA | SOOCHOW UNIVERSITY |
| 18008443 | HUMAN NSCLC CELL LINES AND USES THEREOF | Non-Final OA | SHANGHAI LIDE BIOTECH CO., LTD. |
| 18031771 | HEPATOCYTE-LIKE CELLS | Non-Final OA | Sana Biotechnology, Inc. |
| 17927793 | METHOD OF TRANSFECTING MACROPHAGES | Non-Final OA | The University Court of The University of Edinburgh |
| 17265364 | CELL PRODUCTION METHOD | Non-Final OA | Orizuru Therapeutics, Inc. |
| 17293845 | POLYNUCLEOTIDE FOR SAFER AND MORE EFFECTIVE IMMUNOTHERAPIES | Non-Final OA | FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD |
| 17624084 | TRANSGENIC MAMMALS AND METHODS OF USE THEREOF | Non-Final OA | TRIANNI, INC. |
| 18021685 | EXPANSION CULTURE MEDIUM AND CULTURE METHOD FOR NEURAL CELLS | Non-Final OA | BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE |
| 18026477 | ARTIFICAL LIVER ORGANOIDS AND METHODS OF THEIR PRODUCTION | Non-Final OA | Universitetet i Oslo |
| 17923265 | METHODS FOR DIFFERENTIATING STEM CELLS INTO DOPAMINERGIC PROGENITOR CELLS | Final Rejection | JZ CELL TECHNOLOGIES AB |
| 17911953 | USE OF EPHB4 AS A TARGET IN SCREENING DRUGS OR MODELS FOR INCREASING INSULIN SENSITIVITY | Final Rejection | Institute of Materia Medica, Chinese Academy of Medical Sciences |
| 17270262 | Pharmaceutical Compositions Comprising Integration-Promoting Peptides | Final Rejection | CODE PHARMA BV. |
| 16987086 | GENETIC MARKERS AND USES THEREFOR | Final Rejection | Livestock Improvement Corporation Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy